)
Visual
test
Affimed
Affimed (AFMD) investor relations material
Affimed has been otc
Affimed Leerink’s Global Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Leerink’s Global Healthcare Conference 2025 summary11 Mar, 2025
Leadership and strategic direction
New CEO with extensive experience in biotech fundraising, public offerings, and clinical development, having led multiple companies through significant financing and clinical milestones.
Pipeline prioritization is a key focus, with decisions influenced by investor input and commercial potential of each asset.
AFM24 and AFM28 are receiving the most attention from investors and partners due to promising data and large unmet needs.
Acimtamig may be deprioritized due to its smaller commercial potential, though it remains a topic in partnering discussions.
Investor and partner interests are aligned, with both groups seeking late-phase, differentiated programs.
Clinical program updates and data
AFM24 in combination with atezolizumab shows a 21% ORR and 5.6 months PFS in EGFR wild type NSCLC, and 24% ORR with similar PFS in EGFR mutant patients.
Higher exposure to AFM24 correlates with improved efficacy across ORR, PFS, and OS, prompting a move to a 720 mg dose cohort, pending regulatory approval.
Next AFM24 cohort will exclude prior taxane exposure to potentially enrich for better PFS outcomes.
AFM28 in AML has shown a 40% composite CR rate at 300 mg, with response durations of 2.5–6.5 months, outperforming recent regulatory benchmarks.
Dose escalation for AFM28 continues, with further data expected 6–9 months after enrolling the next cohort.
Differentiation and competitive positioning
NK cell engager approach enables a wider therapeutic index, reducing toxicity compared to T-cell engagers, CAR-Ts, and ADCs targeting CD123.
AFM24 and AFM28 demonstrate lower on-target toxicity, with no typical EGFR-related skin or mucosal side effects.
Both programs are seen as optimal for difficult targets with narrow therapeutic windows, validated by similar approaches from competitors.
Acimtamig, in combination with Artiva’s NK cells, maintains high CR and ORR rates in double refractory Hodgkin’s lymphoma, with durability data pending.
Commercial viability and scalability are prioritized in development decisions, especially regarding NK cell sourcing and dosing regimens.
How does investor feedback shape pipeline choices
AFM24: Why did prior PK/PD modeling fall short?
AFM28: Why delay dose escalation for durability?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebPECO
Record 2025 occupancy and 7% Core FFO growth; 2026 targets 5.5% FFO growth and strong acquisitions. - 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
- 6 FebEMBASSY
Record revenue, NOI, and distributions highlight strong growth and robust segment performance. - 6 FebCRIRevenue fell and losses deepened, but ESA contracts and R&D projects drive future prospects.
- 6 FebTUPRS
Net income reached TRY 29.5 billion, with strong dividends and a robust net cash position.
Affimed
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. The company operates through two segments, Affimed Therapeutics, and Redoxa GmbH. It develops therapies based on its proprietary TandAb platform to unleash the innate power of the immune system by harnessing the functionality of natural killer cells and T-cells for the treatment of cancer.
The company has strategic partnerships with Genentech Inc.; Merck KGaA and Pfizer Inc.; Novartis Institutes for BioMedical Research, Inc.; Celgene Corporation; Bayer Pharma AG; MorphoSys AG; Incyte Corporation; Amgen Inc.; Hoffmann-La Roche ltd; Sanofi S.A.; and Bristol-Myers Squibb Company. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage